Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8XK7F
|
|||
| Drug Name |
RGLS4326
|
|||
| Synonyms |
UNII-UCH3QQH1C0; UCH3QQH1C0; RGLS-4326; 2229964-07-0
Click to Show/Hide
|
|||
| Drug Type |
Oligonucleotide
|
|||
| Indication | Autosomal dominant polycystic kidney disease [ICD-11: GB81; ICD-10: Q61.2; ICD-9: 753.1] | Phase 1 | [1] | |
| Company |
Regulus Therapeutics
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C95H115F3N32O51P8S8
|
|||
| Canonical SMILES |
CC1C2(C(C(O1)C(O2)N3C=NC4=C(N=CN=C43)N)OP(=S)(O)OCC56C(OC(C5OP(=O)(OCC7C(C(C(O7)N8C=CC(=NC8=O)N)OC)OP(=S)(O)OCC9C(C(C(O9)N1C=NC2=C(N=CN=C21)N)F)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)F)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=O)NC1=O)F)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=O)NC1=O)OC)OP(=S)(O)OCC12C(OC(C1OP(=S)(O)OCC13C(OC(C1O)C(O3)N1C=NC3=C1N=C(NC3=O)N)C)C(O2)N1C=CC(=O)NC1=O)C)S)C(O6)N1C=NC2=C1N=C(NC2=O)N)C)CO
|
|||
| InChI |
1S/C95H115F3N32O51P8S8/c1-32-92(22-131)65(61(162-32)83(170-92)128-29-110-50-69(102)106-27-108-71(50)128)179-189(150,197)160-25-95-35(4)164-63(84(173-95)130-31-112-52-73(130)119-86(104)121-75(52)137)67(95)180-186(147,194)157-21-40-56(58(151-5)79(168-40)124-13-8-42(100)114-88(124)139)177-185(146,193)155-19-38-55(48(98)78(167-38)127-28-109-49-68(101)105-26-107-70(49)127)176-183(144,191)154-17-36-53(46(96)76(165-36)122-12-7-41(99)113-87(122)138)174-182(143,190)153-18-37-54(47(97)77(166-37)123-14-9-43(132)115-89(123)140)175-184(145,192)156-20-39-57(59(152-6)80(169-39)125-15-10-44(133)116-90(125)141)178-187(148,195)159-24-94-34(3)163-62(82(172-94)126-16-11-45(134)117-91(126)142)66(94)181-188(149,196)158-23-93-33(2)161-60(64(93)135)81(171-93)129-30-111-51-72(129)118-85(103)120-74(51)136/h7-16,26-40,46-48,53-67,76-84,131,135H,17-25H2,1-6H3,(H,143,190)(H,144,191)(H,145,192)(H,146,193)(H,147,194)(H,148,195)(H,149,196)(H,150,197)(H2,99,113,138)(H2,100,114,139)(H2,101,105,107)(H2,102,106,108)(H,115,132,140)(H,116,133,141)(H,117,134,142)(H3,103,118,120,136)(H3,104,119,121,137)/t32-,33-,34-,35-,36+,37+,38+,39+,40+,46+,47+,48+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64-,65-,66-,67-,76+,77+,78+,79+,80+,81+,82+,83+,84+,92-,93-,94-,95-,182?,183?,184?,185?,186?,187?,188?,189?/m0/s1
|
|||
| InChIKey |
WAVSYQSKUSIMAY-IOHKGNKKSA-N
|
|||
| CAS Number |
CAS 2229964-07-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | microRNA hsa-miR-17 (MIR17) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04536688) A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease. U.S. National Institutes of Health. | |||
| REF 2 | Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.